33 results about "Immunoglobulin Fc Fragments" patented technology

Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.

Disclosed are an Fc fragment modified by a non-peptide polymer, a pharmaceutical composition comprising the Fc fragment modified by the non-peptide polymer as a carrier, a complex of the Fc fragment and a drug via a linker and a pharmaceutical composition comprising such a complex. The Fc fragment modified by a non-peptide peptide according to the present invention lacks immunogenicity and effector functions. Due to these properties, the Fc fragment maintains the in vivo activity of a drug conjugated thereto in high levels, remarkably increases the serum half-life of the drug, and remarkably reduces the risk of inducing immune responses.

A human interleukin 15-Fc fusion protein composed of interleukin 15 and the Fc fragment of human immunoglobulin, which are linked via joining peptide, the nucleic acid ofr coding it, the expression carrier containing said nucleic acid, its composite medicine for preventing and treating microbial infection and its preparing process are disclosed.

Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.

The invention relates to anti viral agents comprised of viral fusion inhibitors and at least a portion of an immunoglobulin constant region. The invention further relates to anti viral agents comprised HIV viral fusion inhibitors and an Fc fragment of an immunoglobulin. The invention also relates to methods of treating a viral infection, including HIV infection.

A human interleukin 15-Fc fusion protein composed of interleukin 15 and the Fc fragment of human immunoglobulin, which are linked via joining peptide, the nucleic acid ofr coding it, the expression carrier containing said nucleic acid, its composite medicine for preventing and treating microbial infection and its preparing process are disclosed.

Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.

The invention provides a fusion protein, a porcine epidemic diarrhea vaccine composition containing the fusion protein and application thereof. The fusion protein contains porcine epidemic diarrhea virus antigenic protein and immunoglobulin Fc segment, wherein the porcine epidemic diarrhea virus antigenic protein contains a protein formed by series combination of porcine epidemic diarrhea virus S protein segments. The invention also provides a porcine epidemic virus vaccine composition which contains the fusion protein and a carrier. The invention also provides a preparation method of the vaccine composition and application of the vaccine composition in preparing drugs for preventing and / or treating diseases initiated by porcine epidemic diarrhea virus. The vaccine composition prepared from the fusion protein avoids the technical problem that the porcine epidemic diarrhea virus totivirus can not be easily separated and cultured in the traditional vaccine inactivation process. The fusion protein can utilize the gene engineering technique to perform abundant recombinant expressions, has the advantage of short time consumption, and is convenient for large-scale production.

The invention discloses hyperglycosylated Extendin-4, fusion protein of analogue thereof, and a preparation method and the application of fusion protein. The fusion protein comprises Extendin-4, the analogue of the Extendin-4, a flexible peptide joint, at least one human chorionic gonadotropin beta carboxyl terminal peptide rigid unit and a human immunoglobulin Fc fragment. The invention also discloses the preparation method and the application of the fusion protein. The fusion protein has optimal biological activity, obviously prolonged circulation half-time, lowered immunogenicity and improved bioavailability. The fusion protein can be used for treating diabetes, obesity and other diseases benefited by lowering fasting plasma glucose, inhibiting stomach and / or bowel movement and inhibiting and / or bowel evacuation or inhibiting food intake.

The present invention relates to a glucagon-like peptide-2 (GLP-2) conjugate comprising native GLP-2 or its derivative and an immunoglobulin Fc fragment being covalently linked via a non-peptidyl polymer, wherein the native GLP-2 or its derivative has a thiol group introduced at its C-terminal end, and one end of the non-peptidyl polymer is linked to an amino acid residue of the GLP-2 other than the N-terminal amino group thereof; a method for preparing the GLP-2 conjugate; a pharmaceutical composition comprising the same; and a method for treating or preventing intestinal disease, intestinal injury, or gastrosia by using the same. Since the GLP-2 conjugate of the present invention has a remarkably increased binding affinity to a GLP-2 receptor, it shows a prolonged in vivo half-life and an improved in vivo durability and stability.

The invention discloses hyperglycosylated human growth hormone fusion protein. The human growth hormone fusion protein sequentially contains a human growth hormone (hGH), a flexible peptide joint (L), human chorionic gonadotropin beta-carboxyl terminal rigid peptide (CTP) and a human immunoglobulin Fc fragment from the N terminal to the C terminal. The invention further discloses a method for efficiently preparing the fusion protein. Compared with a recombinant hGH, the built fusion protein has more excellent in-vivo drug efficacy, the in-vivo circulation half-life period is prolonged, the administration frequency is greatly decreased, and the bioavailability is improved; meanwhile, the production process is simpler and more efficient.

The present invention provides a FGF21 and IGF-1 fusion protein, wherein fusion is performed through an appropriate linker peptide fragment in an optimal fusion manner, and the produced fusion proteinsuccessfully retains the respective biological activities. According to the present invention, specifically the fusion protein sequentially contains human fibroblast growth factor-21 (hFGF21), a flexible peptide linker (L), a human immunoglobulin Fc fragment, a flexible peptide linker (L) and an insulin-like growth factor (IGF-1) from the N terminal to the C terminal; and the fusion protein provides high regulation effect in glycolipid metabolism and the like compared to the single use of the proteins, enhances the treatment effects on metabolic disorders, cardiovascular diseases, liver fat lesions and other diseases, and overcomes the side effects (such as osteoporosis, cancer risk and the like).

The invention discloses high-glycosylation human growth hormone fusion protein. The human growth hormone fusion protein provided by the invention is characterized in that human growth hormone (hGH), flexible peptide joint (L), at least one human chorionic gonadotropin beta-subunit carboxyl terminated rigid peptide (CTP) and human immunoglobulin Fc fragments are sequentially contained from the end N to the end C. The invention also discloses a method for effectively preparing the fusion protein. The built fusion protein has more excellent in vivo medicine effect than recombination hGH; the in vivo circulation half-life period is prolonged; the medication administration frequency is greatly reduced; in addition, the bioavailability is improved; meanwhile, the production process is more simple and efficient.

The invention relates to a fusion protein of an IL-2 mutant and an antibody and application of the fusion protein. The fusion protein is a heterotrimeric protein composed of an IL-2 mutant (sumIL-2) and a tumor treatment antibody, the structure of the heterotrimeric protein is similar to that of the antibody, and the structural diagram is shown in figure 2A. Three monomers of the heterotrimeric protein are respectively as follows: (1) first monomer: fusion protein formed by fusing an IL-2 mutant (sumIL-2) and an immunoglobulin Fc fragment sequentially comprises sumIL-2 and an immunoglobulin Fc region from the N end to the C end; (2) second monomer: a single heavy chain of a tumor treatment antibody sequentially comprises a heavy chain variable region VH, a heavy chain CH region and an immunoglobulin Fc region of the antibody from the N end to the C end, and an immunoglobulin Fc region contained in the second monomer can be paired with an immunoglobulin Fc fragment of the first monomer to form a heterodimer; and (3) third monomer: a single light chain (comprising a VL region and a CL region) of the tumor treatment antibody, wherein the CL region contained in the third monomer can be paired with CH of the second monomer to form a heterodimer with a half-antibody structure; and the tumor treatment antibody is an antibody targeting a high-expression membrane protein on the surface of a tumor cell.

The present invention relates to a method for improving the solubility of a physiologically active protein or peptide compared to that of a physiologically active protein or peptide which is not conjugated to an immunoglobulin Fc fragment, in which the method comprises conjugating the physiologically active protein or peptide to an immunoglobulin Fc fragment; and a composition for improving the solubility of a physiologically active protein or peptide, comprising an immunoglobulin Fc fragment, in which the composition improves the solubility compared to a composition without an immunoglobulin Fc fragment.

The present invention relates to a transformant prepared by introducing an expression vector comprising a polynucleotide encoding for a human immunoglobulin Fc fragment into Pichia sp. yeast, a method for producing an immunoglobulin Fc fragment comprising culturing the transformant, and recovering the immunoglobulin Fc fragment from the culture, and an immunoglobulin Fc fragment, prepared by the above method for use as a drug carrier. The transformant is suggested as a solution to the problems associated with the use of E. coli or animal cells as hosts for producing immunoglobulin Fc fragments useful as drug carriers, so that it can find various applications in the effective and economical production of drugs.

The present invention relates to a physiologically active polypeptide-immunoglobulin Fc fragment conjugate, which comprises a physiologically active polypeptide linked via a non-peptidyl linker to an immunoglobulin Fc fragment having an FcRn-binding region and maintains the intrinsic binding affinity of the immunoglobulin Fc fragment, a method for preparing the conjugate, a method of maintaining the intrinsic binding affinity of the conjugate for FcRn, and a composition comprising the conjugate, which maintains the intrinsic binding affinity of the immunoglobulin Fc fragment for FcRn.

The invention discloses fusion proteins and a preparation method thereof, and application of the fusion proteins to medicines used for treating ophthalmic diseases and resisting inflammations and tumors, belonging to the technical field of biopharmaceuticals. According to the invention, a flexible (F) or rigid (R) linker is used for fusing two polypeptides so as to obtain two bifunctional fusion proteins, respectively; that is, the two angiogenesis-inhibiting polypeptides HM-3 and IL-4 are linked with the Fc fragment of an immunoglobulin in virtue of the amino acid linker so as to form multi-functional fusion protein macromolecules. The fusion proteins can improve drug efficacy, prolong half-life and enhance stability, have the characteristics of strong action, low toxicity and the like, and is applicable to the prevention and treatment of solid tumors, various inflammations and neovascular ophthalmic diseases. The fusion proteins are expressed in eukaryotic cells by using a genetic engineering method and are obtained through affinity chromatographic purification.

Provided are a glucagon-like peptide-2 (GLP-2) conjugate containing native GLP-2 or its derivative and an immunoglobulin Fc fragment being covalently linked via a non-peptidyl polymer, wherein the native GLP-2 or its derivative has a thiol group introduced at its C-terminal end, and one end of the non-peptidyl polymer is linked to an amino acid residue of the GLP-2 other than the N-terminal amino group thereof; a method for preparing the GLP-2 conjugate; a pharmaceutical composition comprising the same; and a method for treating or preventing intestinal disease, intestinal injury, or gastrosis by using the same. Since the GLP-2 conjugate of the present invention has a remarkably increased binding affinity to a GLP-2 receptor, it shows a prolonged in vivo half-life and an improved in vivo durability and stability.

The invention relates to a long-acting human endothelium chalone. The long-acting human endothelium chalone is a human endothelium chalone molecule covalently connected with an immune globulin Fc segment by polyethylene glycol. The invention also discloses a preparation and purification method of the long-acting human endothelium chalone and an application of the long-acting human endothelium chalone in preparation of a drug used for treating cancer.

The invention relates to a technique for transferring Fc segment fusion gene (sSCF-Fc) of human stem cell factor and human immunoglobulin G1 (IgG1) into a mammalian cell for large-scale production of a protein product of the gene, and aims to establish a method for large-scale production of sSCF-Fc protein with biological activity by using the mammalian cell. The experimental technique meets the overall requirements of reducing production cost, simplifying process flow and improving product yield and quality in industrial production. By adopting the method, a large amount of sSCF-Fc protein with high purity and high biological activity can be obtained through normal large-scale cell culture. The technique is applied to large-scale production of the sSCF-Fc protein; and the cost can be obviously reduced, the process flow can be simplified, and the product yield and quality can be improved.

Provided is a long-acting pharmaceutical composition containing a conjugate comprising a physiologically active polypeptide linked to an immunoglobulin Fc fragment, wherein the composition contains a monomeric conjugate comprising one molecule of the physiologically active polypeptide linked to a single immunoglobulin Fc fragment, and optionally contains a multimeric conjugate comprising two or more molecules of the same physiologically active polypeptide linked to a single immunoglobulin Fc fragment, provided that the molar ratio of the monomeric conjugate to the multimeric conjugate in the composition is at least 19; a physiologically active polypeptide monomer-immunoglobulin Fc fragment conjugate that comprises a physiologically active polypeptide monomer linked via a non-peptidyl linker to an immunoglobulin Fc fragment, wherein the physiologically active polypeptide is linked via the non-peptidyl linker to the immunoglobulin Fc fragment in a monomeric form.

The invention discloses a fusion protein of a hepatocyte growth factor receptor active group, and the fusion protein expresses various fusion proteins of single or more hepatocyte growth factor receptor active groups and human immunoglobulin Fc segments in different combinations by utilizing a molecular biology technology. The fusion protein of the hepatocyte growth factor receptor active group can be efficiently and specifically combined with a growth factor, prevents the growth factor from combining with tumor cells, inhibits growth and transfer of the tumor cells, and treats tumor in a target localization way; and due to the diversity of the hepatocyte growth factor receptor active group, the fusion protein with different affinities and pharmacokinetics can be obtained by virtue of the combination of single or more receptor active groups.

The invention provides a recombinant equine chorionic gonadotropin fusion protein as well as a preparation method and application thereof. The recombinant equine chorionic gonadotropin fusion proteinspecifically comprises a reCG-Fc fusion protein, the reCG-Fc fusion protein contains an alpha subunit and a beta-FC subunit, the beta-FC subunit is formed through fusion of an eCG beta subunit and animmune globulin Fc segment, and the alpha subunit is connected with the beta-FC subunit through Van der Waals' force. The reCG-Fc fusion protein is expressed by using a mammal eukaryotic expression system. The reCG-Fc fusion protein prepared in the invention is used in the field of animal breeding, which comprises estrus synchronization and superovulation of dams; and compared with Pregnant Mare Serum Gonadotropin (PMSG) extracted from serum of pregnant mare at present, the recombinant equine chorionic gonadotropin fusion protein is more stable in quality, higher in purity, less in impuritiesand better in pesticide effect, and the fusion protein can be applied in animal breeding instead of PMSG.

The present invention relates to a transformant prepared by introducing an expression vector comprising a polynucleotide encoding for a human immunoglobulin Fc fragment into Pichia sp. yeast, a method for producing an immunoglobulin Fc fragment comprising culturing the transformant, and recovering the immunoglobulin Fc fragment from the culture, and an immunoglobulin Fc fragment, prepared by the above method for use as a drug carrier. The transformant is suggested as a solution to the problems associated with the use of E. coli or animal cells as hosts for producing immunoglobulin Fc fragments useful as drug carriers, so that it can find various applications in the effective and economical production of drugs.

The invention provides a fusion protein, porcine epidemic diarrhea vaccine composition containing the fusion protein and application thereof. The fusion protein contains porcine epidemic diarrhea virus antigenic protein and immunoglobulin Fc fragment, and the porcine epidemic diarrhea virus antigenic protein contains a protein formed by series combination of porcine epidemic diarrhea virus S protein fragments. The invention also provides a porcine epidemic virus vaccine composition, which contains fusion protein and carrier. The invention also discloses the preparation method of the vaccine composition and its application in the preparation of medicines for preventing and / or treating diseases caused by porcine epidemic diarrhea virus. The vaccine composition prepared by the fusion protein avoids the technical difficulty of separating and cultivating the whole virus in the process of preparing the traditional inactivated vaccine with the whole virus of porcine epidemic diarrhea virus; It is time consuming and also facilitates mass production.

The invention relates to a technology for transferring an Fc segment fusion gene (VEGF165-Fc) of a human recombinant human vascular endothelial growth factor 165 and a human immune globulin IgG1 into mammalian cells so as to produce the protein products in a large scale. The invention aims to establish a method for producing VEGF165-Fc proteins with biological activity in a large scale by using the mammalian cells. The overall requirements of lowering production cost, simplifying process flow and improving product yield and quality are met in industrial production. By the method, a great number of VEGF165-Fc proteins with high purity and high biological activity are obtained by using common large-scale cell culture. The technology is applied to the large-scale production of the VEGF165-Fc proteins. By the technology, the cost can be obviously lowered, a process flow is simplified, and the yield and the quality of the products are improved.

The invention relates to a technique for transferring a human recombinant fusion gene (VEGF-FC) of a human vascularendothelial growth factor (VEGF) 121 and the Fc fragment of human immunoglobulin IgG1 into a mammalian cell for mass production of its protein products. The invention aims to establish a method for mass production of a biologically active VEGF121-FC protein with a mammalian cell. The invention can satisfy the general requirements of reducing production cost, simplifying technical process, as well as improving product output and quality during industrial production. With the technique of the invention, a lot of high purity and highly biologically active VEGF121-FC proteins can be obtained through ordinary large scale cell culture. Application of the technique provided in the invention to large scale production of the VEGF121-FC protein can substantially reduce lost, simplify technical process, as well as improve product output and quality.

The invention discloses a compound containing an immunoglobulin Fc segment and a granulocyte macrophage-colony stimulating factor and a pharmaceutical composition of the compound. The immunoglobulin Fc segment is connected with the granulocyte macrophage-colony stimulating factor through a chemical molecule, wherein the chemical molecule can be a polyethylene glycol polymer. According to the compound and the pharmaceutical compositions of the compound, the serum half-life of the granulocyte macrophage-colony stimulating factor can be remarkably prolonged while the higher level biological activity of the granulocyte macrophage-colony stimulating factor is maintained. Compared with a traditional PEG (Polyethylene Glycol)-granulocyte macrophage-colony stimulating factor, the compound has better uniformity.

The invention discloses a CBLB502-Fc fusion protein and a preparation method thereof. The fusion protein comprises CBLB502 protein and an immune globulin Fc segment, wherein the Fc segment is selected from immune globulin of human or animals or subtypes thereof. The fusion protein with high activity, good stability and long half-life period is obtained by building a eukaryotic expression vector of the CBLB502-Fc fusion protein and transfecting to eukaryotic cells, and can be applied to radiation protection, remission and restoration of bone marrow and gastrointestinal tract injuries caused by chemical medicines, tumor prevention and the like.